Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $572000.0.

  • Lyell Immunopharma's Change in Accured Expenses fell 8151.26% to $572000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year decrease of 69538.9%. This contributed to the annual value of -$1.2 million for FY2024, which is 7385.26% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Change in Accured Expenses stood at $572000.0, which was down 8151.26% from -$3.3 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Change in Accured Expenses registered a high of $5.4 million during Q4 2022, and its lowest value of -$9.8 million during Q1 2025.
  • Its 5-year average for Change in Accured Expenses is -$549263.2, with a median of $516000.0 in 2024.
  • As far as peak fluctuations go, Lyell Immunopharma's Change in Accured Expenses soared by 39608.36% in 2023, and later crashed by 74534.88% in 2025.
  • Over the past 5 years, Lyell Immunopharma's Change in Accured Expenses (Quarter) stood at $4.2 million in 2021, then rose by 27.41% to $5.4 million in 2022, then crashed by 132.37% to -$1.7 million in 2023, then rose by 27.89% to -$1.3 million in 2024, then skyrocketed by 145.61% to $572000.0 in 2025.
  • Its Change in Accured Expenses was $572000.0 in Q3 2025, compared to -$3.3 million in Q2 2025 and -$9.8 million in Q1 2025.